CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Riluzoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02019940
NCT02019940Phase 1Completed
CompareCT.gov

An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)

Yale University·interventional·Posted Dec 24, 2013·Updated Apr 1, 2020

In Brief

A Phase 1 clinical trial evaluating Riluzole for PTSD. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States
CollaboratorsNational Center for PTSD

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 24, 2013
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 12.5 years ago

Interventions

Riluzoledrug